Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C12N7/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/008267VIRUS AND TUMOR THERAPEUTIC DRUG FOR SPECIFICALLY KILLING TUMOR CELLS
WO 21.01.2021
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CN2020/094435 Applicant WU, Zetang Inventor WU, Zetang
Provided are a virus and a tumor therapeutic drug for specifically killing tumor cells The virus is a recombinant oncolytic virus, and the genome thereof has an exogenous promoter which is located upstream of an essential gene of the virus to substitute the native promoter of the essential gene, and to drive the expression of the essential gene in tumor cells but not in normal cells. The virus can specifically kill various tumor cells, has a high killing efficiency of tumor cells and is safe for non-tumor cells.
2.WO/2021/009302HOST-INDEPENDENT EXPRESSION OF BACTERIOPHAGES
WO 21.01.2021
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/EP2020/070178 Applicant TECHNISCHE UNIVERSITÄT MÜNCHEN Inventor VOGELE, Kilian
The present invention relates to a method for producing a bacteriophage in a cell-free host- independent expression system and a corresponding composition comprising a cell lysate of an organism which is different to the host of the bacteriophage, a at least one bacteriophage- host specific factor and a genome of a bacteriophage. The respective kits are also encompassed. The invention moreover refers to a bacteriophage obtained by the method of the invention and uses thereof.
3.WO/2021/009301METHOD FOR PRODUCING A MODIFIED BACTERIOPHAGE WITHOUT GENOME MODIFICATION
WO 21.01.2021
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/EP2020/070177 Applicant TECHNISCHE UNIVERSITÄT MÜNCHEN Inventor VOGELE, Kilian
The invention relates to a method for producing a modified bacteriophage in a cell-free expression system wherein the expression of at least one gene of interest is suppressed by a molecule specifically inhibiting its expression. The invention further relates to a composition and a kit for producing a modified bacteriophage. Moreover, the invention relates to a bacteriophage which is not modified on the genomic level but on the proteomic level and its use for therapy, for diagnostic and detection assays.
4.WO/2021/011941USE OF ION CONCENTRATIONS TO INCREASE THE PACKAGING EFFICIENCY OF RECOMBINANT ADENO-ASSOCIATED VIRUS
WO 21.01.2021
Int.Class C12N 7/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
02Recovery or purification
Appl.No PCT/US2020/045906 Applicant VIGENE BIOSCIENCES INC. Inventor WANG, Qizhao
The present invention is directed to methods for increasing the efficiencies with which recombinant adeno-associated virus (rAAV) are packaged, so as to increase their production titers. More specifically, the invention relates to a method for increasing the production titer of rAAV by transfected cells by increasing the ionic strength of the cell culture media through the administration of additional ions.
5.WO/2021/011436SEPARATION AND QUANTIFICATION OF EMPTY AND FULL VIRAL CAPSID PARTICLES
WO 21.01.2021
Int.Class B01D 15/16
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
DSEPARATION
15Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
08Selective adsorption, e.g. chromatography
10characterised by constructional or operational features
16relating to the conditioning of the fluid carrier
Appl.No PCT/US2020/041741 Applicant SANGAMO THERAPEUTICS, INC. Inventor KHATWANI, Santoshkumar
The present disclosure provides methods for the separation and quantification of empty and full viral capsids (e.g., AAV capsids) within a viral preparation, such as a viral pharmaceutical composition or drug product.
6.WO/2021/010595NOVEL ENTEROBACTER AEROGENES BACTERIOPHAGE ENT-AEP-1, AND USE THEREOF FOR INHIBITING GROWTH OF ENTEROBACTER AEROGENES AND ENTEROBACTER CLOACAE BACTERIA
WO 21.01.2021
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/KR2020/007448 Applicant INTRON BIOTECHNOLOGY, INC. Inventor YOON, Seong Jun
The present invention relates to: siphoviridae bacteriophage Ent-AEP-1 (accession number KCTC 13569BP) which is isolated from nature and characterized by having the ability to kill enterobacter aerogenes bacteria and enterobacter cloacae bacteria, and having a genome represented by SEQ ID NO: 1; and a method for using a composition including same as an active ingredient to prevent and treat diseases caused by the enterobacter aerogenes bacteria or the enterobacter cloacae bacteria.
7.WO/2021/008269ONCOLYTIC VIRUS AND APPLICATION THEREOF, AND DRUG FOR TREATING CANCER
WO 21.01.2021
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CN2020/094751 Applicant WU, Zetang Inventor WU, Zetang
Provided are an oncolytic virus and an application thereof, and a drug for treating a cancer. A first regulation element and a second regulation element are inserted into the genome of the oncolytic virus. The first regulation element comprises a cancer cell specific promoter sequence and a first nucleic acid sequence driven by the cancer cell specific promoter to express specific protease in cancer cells; the second regulation element comprises a second nucleic acid sequence for encoding an extracellular traction signal peptide and a third nucleic acid sequence for encoding a specific cleavage site. The oncolytic virus can be replicated in cancer cells with high replication capability to kill host cancer cells, and has reliable safety to non-cancer cells.
8.WO/2021/010369METHOD FOR DETECTING CIRCULATING TUMOR CELLS USING VIRUS
WO 21.01.2021
Int.Class C12N 5/09
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
09Tumour cells
Appl.No PCT/JP2020/027203 Applicant JUNTENDO EDUCATIONAL FOUNDATION Inventor OKABE Takahiro
[Problem] To provide a method for detecting circulating tumor cells. [Solution] This method for detecting a circulating tumor cell includes (a) a step for preparing a test sample by subjecting a blood sample to density-gradient centrifugation in the presence of a crosslinking agent for erythrocytes and leukocytes and thereby removing blood cells, (b) a step for infecting the test sample prepared in step (a) with a virus, (c) a step for labeling the test sample obtained in step (b), and (d) a step for detecting circulating tumor cells in the test sample obtained in step (c).
9.WO/2021/007647GENETICALLY ENGINEERED BACTERIOPHAGE
WO 21.01.2021
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CA2019/050992 Applicant CYTOPHAGE TECHNOLOGIES Inventor THERIAULT, Steven
A method of engineering bacteriophages comprising isolating a bacteriophage; removing all attachment genes from a genome of said bacteriophage; inserting a first unique open reading frame encoding one or more attachment genes and inserting a second unique open reading frame encoding one or more genes useful for overcoming bacterial defenses; and inserting a non-natural attachment gene into said first open reading frame, wherein said non-natural attachment gene is specific for attaching to a selected bacteria.
10.WO/2021/009805ADENO-ASSOCIATED VIRUS VIRION FOR GENE TRANSFER TO HUMAN LIVER
WO 21.01.2021
Int.Class C12N 15/864
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
864Parvoviral vectors
Appl.No PCT/JP2019/027717 Applicant GENE THERAPY RESEARCH INSTITUTION CO., LTD. Inventor MURAMATSU Shin-ichi
The present application provides a modified adeno-associated virus vector that efficiently transfers genes to a liver in a living body (human, for example) by reducing the attack from neutralizing antibodies in blood. More specifically, the present application provides an adeno-associated virus vector that includes a capsid protein including an amino acid sequence represented by SEQ ID NO: 2 or 3 with at least one of serine at position 472, serine at position 587, and asparagine at position 706 substituted with another amino acid, and 1 to 6 amino acid residues at other residue positions deleted, substituted or inserted. The adeno-associated virus vector does not cross-react with neutralizing antibodies against AAV2.